Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects.
作者： Benny Sørensen , Peter Johansen , Gitte L Nielsen , Jens C Sørensen , Jørgen Ingerslev
DOI: 10.1097/00001721-200307000-00007
关键词:
摘要: Major bleeding is a frequent and hazardous complication associated with thromboprophylaxis using vitamin-K antagonists (VKA). Suggested regimens for control of highly elevated International Normalized Ratio (INR) hemorrhagic events during VKA treatment include administration vitamin K, infusion fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC). In contrast, this communication present the first report on efficacious use recombinant factor VIIa (rFVIIa) as additional therapy in seven patients presenting central nervous system (CNS) emergencies. Pre-treatment INRs ranged from 1.7 to 6.6, 10 min after single dose rFVIIa (10-40 microg/kg) all were
sci-hub.se 参考文章(32)
B. Sørensen, P. Johansen, K. Christiansen, M. Woelke, J. Ingerslev, Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. Journal of Thrombosis and Haemostasis. ,vol. 1, pp. 551- 558 ,(2003) , 10.1046/J.1538-7836.2003.00075.X
Richard H White, Tara McKittrick, Rose Hutchinson, Jeff Twitchell, Temporary Discontinuation of Warfarin Therapy: Changes in the International Normalized Ratio Annals of Internal Medicine. ,vol. 122, pp. 40- 42 ,(1995) , 10.7326/0003-4819-122-1-199501010-00006
U. Hedner, NovoSeven as a universal haemostatic agent. Blood Coagulation & Fibrinolysis. ,vol. 11, ,(2000) , 10.1097/00001721-200004001-00020
Celeste M Lindley, William T Sawyer, B Gail Macik, Jean Lusher, Justin F Harrison, Kelly Baird-Cox, Kel Birch, Stephen Glazer, Harold R Roberts, Pharmacokinetics and pharmacodynamics of recombinant factor VIIa Clinical Pharmacology and Therapeutics. ,vol. 55, pp. 638- 648 ,(1994) , 10.1038/CLPT.1994.80
Jørgen Ingerslev, Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Seminars in Thrombosis and Hemostasis. ,vol. 26, pp. 425- 432 ,(2000) , 10.1055/S-2000-8463
Harold R Roberts, Recombinant factor VIIa (NovoSeven®) and the safety of treatment Seminars in Hematology. ,vol. 38, pp. 48- 50 ,(2001) , 10.1016/S0037-1963(01)90148-9
Erik Berntorp, Recombinant FVIIa in the treatment of warfarin bleeding. Seminars in Thrombosis and Hemostasis. ,vol. 26, pp. 433- 433 ,(2000) , 10.1055/S-2000-8464
F. H. STEFFENSEN, K. KRISTENSEN, E. EJLERSEN, J. F. DAHLERUP, H. T. SØRENSEN, Major haemorrhagic complications during oral anticoagulant therapy in a Danish Population-based cohort Journal of Internal Medicine. ,vol. 242, pp. 497- 503 ,(1997) , 10.1111/J.1365-2796.1997.TB00023.X
G. Muleo, R. Santoro, P. G. Iannaccaro, P. Papaleo, F. Leo, D. Zappala, L. Elia, Small doses of recombinant factor VIIa in acquired deficiencies of vitamin K dependent factors. Blood Coagulation & Fibrinolysis. ,vol. 10, pp. 521- 522 ,(1999) , 10.1097/00001721-199912000-00010
Dougald M. Monroe, Maureane Hoffman, Julie A. Oliver, Harold R. Roberts, Platelet activity of high‐dose factor VIIa is independent of tissue factor British Journal of Haematology. ,vol. 99, pp. 542- 547 ,(1997) , 10.1046/J.1365-2141.1997.4463256.X